FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...
Roche said the late-stage trial did not provide reliable evidence that the drug's use in combination with Pfizer's Ibrance ...
Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...
Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the ...
Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results